HYPOPHARYNX SQUAMOUS CELL CARCINOMA
Clinical trials for HYPOPHARYNX SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HYPOPHARYNX SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HYPOPHARYNX SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New weekly combo may offer hope for head and neck cancer patients who can't take standard chemo
Disease control Recruiting nowThis study tests a weekly treatment of two chemotherapy drugs (carboplatin and paclitaxel) plus an immunotherapy drug (pembrolizumab) in 32 people with advanced head and neck cancer that has spread. It is for patients who cannot take the standard drug 5-fluorouracil. The goal is …
Matched conditions: HYPOPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug combo aims to shrink Hard-to-Treat head and neck tumors
Disease control Recruiting nowThis study tests whether combining two drugs, sacituzumab govitecan and cetuximab, can shrink tumors in people with advanced head and neck cancer that has returned or spread after initial treatment. About 40 adults whose cancer worsened after first-line therapy will receive the c…
Matched conditions: HYPOPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Study aims to spare cancer patients from unnecessary radiation side effects
Disease control Recruiting nowThis study is testing a new way to decide which parts of the neck need radiation treatment for head and neck cancer. Doctors will use a small biopsy to check lymph nodes, hoping to avoid radiating healthy areas. The goal is to control the cancer just as well as standard treatment…
Matched conditions: HYPOPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC